These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24450727)

  • 1. Comparison of digital planimetry and ruler technique to measure ABSSSI lesion sizes in the ESTABLISH-1 study.
    Bien P; De Anda C; Prokocimer P
    Surg Infect (Larchmt); 2014 Apr; 15(2):105-10. PubMed ID: 24450727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
    De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
    Medicine (Baltimore); 2017 Dec; 96(52):e9163. PubMed ID: 29384903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain.
    Powers JH; Das AF; De Anda C; Prokocimer P
    Contemp Clin Trials; 2016 Sep; 50():265-72. PubMed ID: 27530088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
    Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
    J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials.
    Sandison T; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
    McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL
    BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
    Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
    Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
    Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.
    McBride D; Krekel T; Hsueh K; Durkin MJ
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):331-337. PubMed ID: 28140693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
    O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
    Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection.
    Covington P; Davenport JM; Andrae D; O'Riordan W; Liverman L; McIntyre G; Almenoff J
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5790-7. PubMed ID: 21947389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections.
    Gras J
    Drugs Today (Barc); 2014 Nov; 50(11):729-37. PubMed ID: 25525633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.
    Ortiz-Covarrubias A; Fang E; Prokocimer PG; Flanagan SD; Zhu X; Cabré-Márquez JF; Tanaka T; Passarell J; Fiedler-Kelly J; Nannini EC
    Braz J Infect Dis; 2016; 20(2):184-92. PubMed ID: 26859064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
    Amara S; Adamson RT; Lew I; Huang X
    Curr Med Res Opin; 2013 Jul; 29(7):869-77. PubMed ID: 23659559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials.
    Moran GJ; De Anda C; Das AF; Green S; Mehra P; Prokocimer P
    Infect Dis Ther; 2018 Dec; 7(4):509-522. PubMed ID: 30242736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials.
    Nathwani D; Corey R; Das AF; Sandison T; De Anda C; Prokocimer P
    Clin Infect Dis; 2017 Jan; 64(2):214-217. PubMed ID: 28003218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.